Comparing continuous and fixed duration myeloma treatment with triplets and doublets
What leads to shorter progression-free survival in CLL patients?
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
ASH highlights in CLL and lymphoma by Dr Andrew Zelenetz
Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL